Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Glycomed Downsizes In Faces Of Competition

Glycomed downsizes in face of competition

Glycomed Inc. is trimming its sails, dropping its Astenose heparinoid compound and cutting back from three simultaneous development programs to two.

An NDA filing is still planned for Galardin, which is in Phase III trials for corneal ulcers. About 490 patients have been enrolled, and the company plans to complete enrollment at the

Read the full 596 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers